IMMUNOLOGY2026™ Conference Recordings For Attendees-KRAS G12D Blocks Erythroid Differentiation and Promotes Inflammatory Pathways at the Single Cell Level in Myeloid Malignancies

KRAS G12D Blocks Erythroid Differentiation and Promotes Inflammatory Pathways at the Single Cell Level in Myeloid Malignancies

Back to course

Video Transcription

Video Summary

The talk described how the KRAS-G12D mutation drives abnormal myeloid development in MDS and AML, causing immature blast expansion, treatment resistance, cytopenias, and poor survival. Using combined transcriptomic and genotyping analysis (GOT), the speaker showed KRAS-mutant AML cells were enriched for inflammatory, TNF/NF-kappaB, and CD83-associated programs. CD83 marked inflammatory, stem-like mutant cells and was elevated in patient samples and a mouse model. KRAS inhibition reduced mutant clones, inflammatory genes, monocytes, and tumor burden while restoring erythroid differentiation. The study suggests KRAS-G12D is an early driver of inflammatory myeloid disease and may be therapeutically targetable.

Meta Tag

Date April 18, 2026 9:45 AM - 10:00 AM

Room 102

Session Animal Models and Multi-omics Technology

Speaker Leah Kravets

Track Immune Mechanisms of Human Disease (HUM)

Year 2026

Keywords

KRAS-G12D

myeloid development

AML

inflammatory signaling

targeted therapy

April 18, 2026 9:45 AM - 10:00 AM

102

Animal Models and Multi-omics Technology

Leah Kravets

Immune Mechanisms of Human Disease (HUM)

2026